TSE:INInMed Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeC$0.25MA: C$2.07▼C$9.1952-Week Range N/AVolume8,004 shsAverage Volume6,583 shsMarket CapitalizationC$44.79 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals. Previous Next 3.2 Community Rank Outperform VotesInMed Pharmaceuticals has received 7 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInMed Pharmaceuticals has received 4 “underperform” votes. (Add your “underperform” vote.)Community SentimentInMed Pharmaceuticals has received 63.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about InMed Pharmaceuticals and other stocks. Vote “Outperform” if you believe IN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -95.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -95.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:IN Previous Symbol CUSIPN/A CIKN/A Webwww.inmedpharma.com Phone604-669-7207Debt Debt-to-Equity Ratio4.74 Current Ratio5.25 Quick Ratio5.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow159.30 Book ValueC$1.85 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees4 Outstanding Shares5,220,720Market CapC$44.79 million Next Earnings Date9/17/2020 (Estimated) OptionableNot Optionable TSX:IN Rates by TradingView Receive IN News and Ratings via Email Sign-up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter. InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of InMed Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMed Pharmaceuticals. When is InMed Pharmaceuticals' next earnings date? InMed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, September 17th 2020. View our earnings forecast for InMed Pharmaceuticals. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc (TSE:IN) issued its earnings results on Thursday, May, 14th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). View InMed Pharmaceuticals' earnings history. Has InMed Pharmaceuticals been receiving favorable news coverage? Press coverage about IN stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. InMed Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about InMed Pharmaceuticals. Who are some of InMed Pharmaceuticals' key competitors? Some companies that are related to InMed Pharmaceuticals include Green Organic Dutchman (TGOD), ESSA Pharma (EPI), Probiotec (PBP), cbdMD (YCBD), Althea Group (AGH), Shield Therapeutics (STX), WeedMD (WMD), Delta 9 Cannabis (NINE), Supreme Cannabis (FIRE), Flowr (FLWR), Biosyent (RX), Venture Life Group (VLG), MMJ Group (MMJ), Auscann Group (AC8) and Acerus Pharmaceuticals (ASP). View all competitors. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Canopy Growth (WEED), Cara Therapeutics (CARA), Hexo (HEXO), InMed Pharmaceuticals (IMLFF), Insys Therapeutics (INSY), Kirkland Lake Gold (KL), Lithium Americas (LAC), NVIDIA (NVDA) and Prophecy Development (PCY). Who are InMed Pharmaceuticals' key executives? InMed Pharmaceuticals' management team includes the following people: Mr. Eric A. Adams, Pres, CEO & Director (Age 56)Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory AffairsMr. Joshua Blacher, Chief Bus. Officer (Age 46)Dr. Eric C. Hsu, Sr. VP of Preclinical R&D What is InMed Pharmaceuticals' stock symbol? InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN." How do I buy shares of InMed Pharmaceuticals? Shares of IN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How big of a company is InMed Pharmaceuticals? InMed Pharmaceuticals has a market capitalization of C$0.00. InMed Pharmaceuticals employs 4 workers across the globe. What is InMed Pharmaceuticals' official website? The official website for InMed Pharmaceuticals is www.inmedpharma.com. How can I contact InMed Pharmaceuticals? The company can be reached via phone at 604-669-7207. This page was last updated on 7/16/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
